Hyalubrix 60

Hyalubrix 60 (also marketed as Hyalone) is a sterile, non-pyrogenic, viscoelastic medical device consisting of a 1.5% solution of high molecular weight (>1500 kDa) non-modified sodium hyaluronate (60 mg/4 mL) obtained via bacterial fermentation. Developed and manufactured by Fidia Farmaceutici, it is administered as a single intra-articular injection to temporarily replace synovial fluid in patients suffering from degenerative or mechanical arthropathy of the knee and hip (osteoarthritis). Its primary mechanism of action is viscosupplementation, which restores the viscoelastic properties of the synovial fluid, reduces joint pain, and improves mobility. Hyalubrix 60 has been evaluated in clinical trials, including a Phase II randomized controlled trial conducted by St. Catherine Specialty Hospital comparing its efficacy to autologous microfragmented adipose tissue (MFAT) in patients with Kellgren-Lawrence Grade 2-3 knee osteoarthritis.

Brand names

Hyalubrix 60Hyalubrix60Hyalubrix-60HyaloneHyalubrix

Other names

hyaluronic acid sodium salt 1.5% solutionsodium hyaluronate 1.5% solution